Primary Aldosteronism: Where Are We Now? Where to from Here?

Abstract

The past nine years have seen major advances in establishing the etiology of unilateral primary aldosteronism, and very possibly that of bilateral hyperaldosteronism, in response to somatic mutations in aldosterone synthase expressing cells. Though there have been important advances in the management of primary aldosteronism, in small but convincing studies, they represent minor changes to current guidelines. What has been totally absent is consideration of the public health issue that primary aldosterone represents, and the public policy issues that would be involved in addressing the disorder. In his introduction to PiPA 6, Martin Reincke calculated that only one in a thousand patients in Germany with primary aldosteronism were treated appropriately, an astounding figure for any disease in the 21st century. Towards remedying this totally unacceptable public health issue, the author proposes a radical simplification and streamlining of screening for primary aldosteronism, and the management of most patients by general practitioners. The second bottle-neck in current management is that of mandatory adrenal venous sampling for all but 1–2% of patients, a costly procedure requiring rare expertise. Ideally, it should be reserved – on the basis of likelihood, enhanced imaging, or peripheral steroid profiles – for a small minority of patients with clear evidence for unilateral disease. Only when costs are minimized and roadblocks removed will primary aldosteronism be properly treated as the public health issue that it is.

Key words

somatic mutations - screening - lateralization - public health - health policy

Publikationsverlauf

Eingereicht: 20. November 2019

Angenommen: 10. Februar 2020

Artikel online veröffentlicht:
04. Mai 2020

• References

• 1 Choi M, Scholl UI, Yue P. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
• 2 Boulkroun S, Beuschlein F, Rossi GP. et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-598
• 3 Azizan EA, Murthy M, Stowasser M. et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59: 587-591
• 4 Azizan EA, Lam BY, Newhouse SJ. et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97: E819-E829
• 5 Monticone S, Hattangady NG, Nishimoto K. et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 97: E1567-E1572
• 6 Åkerström T, Crona J, Delgado Verdugo A. et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7: e41926
• 7 Geller DS, Zhang J, Wisgerhof MV. et al. A novel form of human mendelian hypertension featuring nonglucocorticoidremediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-3123
• 8 Stowasser M, Gordon RD, Tunny TJ. et al. Familial hyperaldosteronism type II: Five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19: 319-322
• 9 Taguchi R, Yamada M, Nakajima Y. et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-1319
• 10 Zheng FF, Zhu LM, Nie AF. et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone producing adenoma. Hypertension 2015; 65: 622-628
• 11 Scholl UI, Goh G, Stölting G. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45: 1050-1054
• 12 Scholl UI, Stölting G, Nelson-Williams C. et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 2015; 4: e06315
• 13 Azizan EA, Poulsen H, Tuluc P. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
• 14 Beuschlein F, Boulkroun S, Osswald A. et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444
• 15 Åkerström T, Maharjan R, Sven Willenberg H. et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep 2016; 6: 19546
• 16 Scholl UI, Stölting G, Schewe J. et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 2018; 50: 349-354
• 17 Fernandes-Rosa FL, Daniil G, Orozco IJ. et al. A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism. Nat Genet 2018; 50: 355-361
• 18 Nanba K, Blinder AR, Rege J. et al. Somatic CACNA1H mutation as a cause of aldosterone-producing adenoma. Hypertension 2020; 75: 645-649
• 19 Nanba K, Omata K, Else T. et al. Targeted molecular characterization of aldosterone-producing adenomas in white Americans. J Clin Endocrinol Metab 2018; 103: 3869-3876
• 20 Nanba K, Omata K, Gomez-Sanchez CE. et al. Genetic Characteristics of aldosterone-producing adenomas in blacks. Hypertension 2019; 73: 885-892
• 21 Nishimoto K, Tomlins SA, Kuick R. et al. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112: E4591-E4599
• 22 Omata K, Anand SK, Hovelson DH. et al. Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals. J Endocr Soc 2017; 1: 787-799
• 23 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
• 24 Ahmed AH, Cowley D, Wolley M. et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: A preliminary study. J Clin Endocrinol Metab 2014; 99: 2745-2753
• 25 Stowasser M, Ahmed AH, Cowley D. et al. Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 2018; 103: 4113-4124
• 26 Gouli A, Kaltsas G, Tzonou A. et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41: 1227-1236
• 27 Markou A, Sertedaki A, Kaltsas G. et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100: 2857-2864
• 28 Helber A, Wambach G, Hummerich W. et al. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58: 439-447
• 29 Baudrand R, Guarda FJ, Fardella C. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension 2017; 69: 950-956
• 30 Stowasser M, Sharman J, Leano R. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
• 31 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
• 32 Milliez P, Girerd X, Plouin PF. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
• 33 Savard S, Amar L, Plouin PF. et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62: 331-336
• 34 Monticone S, D'Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
• 35 Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e15985
• 36 Rakugi H, Ito S, Itoh H. et al. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res 2019; 42: 1932-1941
• 37 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection diagnosis and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 38 Burton TJ, Mackenzie IS, Balan K. et al. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2012; 97: 100-109
• 39 Abe T, Naruse M, Young WF. et al. A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism. J Clin Endocrinol Metab 2016; 101: 1008-1015
• 40 Satoh F, Morimoto R, Ono Y. et al. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 2015; 65: 1096-1102
• 41 Nishikawa T, Omura M, Satoh F. et al. Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J 2011; 58: 711-721
• 42 Mulatero P, Monticone S, Burrello J. et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253-2257
• 43 Funder JW. Primary Aldosteronism. Hypertension 2019; 74: 458-466
• 44 Dostanic-Larson I, Vay Huysse JW, Lorenz JN. et al. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci U S A 2005; 102: 15845-15850